Article
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Cancer research - 15 May 2007
Ji Hongbin, Wang Zhenxiong, Perera Samanthi A, Li Danan, Liang Mei-Chih, Zaghlul Sara, McNamara Kate, Chen Liang, Albert Mitchell, Sun Yanping, Al-Hashem Ruqayyah, Chirieac Lucian R, Padera Robert, Bronson Roderick T, Thomas Roman K, Garraway Levi A, Jänne Pasi A, Johnson Bruce E, Chin Lynda, Wong Kwok-Kin
Abstract excerpt
Mutations in the BRAF and KRAS genes occur in approximately 1% to 2% and 20% to 30% of non-small-cell lung cancer patients, respectively, suggesting that the mitogen-activated protein kinase (MAPK) pathway is preferentially activated in lung cancers. Here, we show that lung-specific expression of the BRAF V600E mutant induces the activation of extracellular signal-regulated kinase (ERK)-1/2 (MAPK) pathway and the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.